Recombinant antibodies and in vitro selection technologies

Methods in Molecular Biology

Volumn 901, Issue , 2012, Pages 11-32

  Geyer, C Ronald ^a   McCafferty, John ^b   Dübel, Stefan ^c   Bradbury, Andrew R M ^d   Sidhu, Sachdev S ^e  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antibodies; In vitro selection; Phage display

Indexed keywords

ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PEPTIDE LIBRARY; REVIEW;

ANIMALS; ANTIBODIES; HUMANS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS;

EID: 84864137357     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-931-0_2     Document Type: Review

References (194)

1. von Behring E, Kitasato S (1890) Über das zustandekommen Der diphtherie-immunität und Der tetanus-immunität bei thieren. Deut Med Wochenzeitschr 16:1113-1114
2. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
3. Courtenay-Luck NS, Epenetos AA, Moore R et al (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493
4. Tjandra JJ, Ramadi L, McKenzie IF (1990) Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 68:367-376
5. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619-1633
6. Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10
7. Kashmiri SVS, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting-a new approach to antibody humanization. Methods 36:25-34
8. Studnicka GM, Soares S, Better M et al (1994) Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng 7:805-814
9. Osbourn J, Groves M, Vaughan T (2005) From rodent reagents to human therapeutics using antibody guided selection. Methods 36: 61-68
10. Fishwild DM, O'Donnell SL, Bengoechea T et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14:845-851
11. Jakobovits A (1995) Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol 6:561-566
12. Kuroiwa Y, Kasinathan P, Sathiyaseelan T et al (2009) Antigen specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol 27:173-181
13. Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13:65-93
14. Weiner LM (2006) Fully human therapeutic monoclonal antibodies. J Immunother 29:1-9
15. Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293-299
16. McCafferty J, Griffiths AD, Winter G et al (1990) Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348:552-554
17. Marks JD, Hoogenboom HR, Bonnert TP et al (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Bio 222:581-597
18. Breitling F, Dübel S, Seehaus T (1991) A surface expression vector for antibody screening. Gene 104:147-153
19. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553-557
20. Feldhaus MJ, Siegel RW, Opresko LK et al (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 21:163-170
21. He M, Taussig MJ (2007) Rapid discovery of protein interactions by cell-free protein technologies. Biochem Soc Trans 35:962-965
22. Jostock T, Dübel S (2005) Screening of molecular repertoires by microbial surface display. Comb Chem High Throughput Screen 8:127-133
23. Paschke M (2006) Phage display systems and their applications. Appl Microbiol Biotechnol 70:2-11
24. Zahnd C, Amstutz P, Pluckthun A (2007) Ribosome display: Selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 4:269-279
25. Chao G, Lau WL, Hackel BJ et al (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1: 755-768
26. Benhar I (2007) Design of synthetic antibody libraries. Expert Opin Biol Ther 7:763-779
27. Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29-49
28. Dübel S, Stoevesandt O, Taussig MJ et al (2010) Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 28:333-339
29. Mersmann M, Meier D, Mersmann J et al (2010) Towards proteome scale antibody selections using phage display. New Biotechnol 27:118-128
30. Scho field DJ et al (2007) Application of phage display to high throughput antibody generation and characterization. Genome Biol 8:R254
31. Colwill K, Gräslund S, Persson MA et al (2011) A roadmap to generate renewable protein binders to the human proteome. Nat Methods 8:551-561
32. Hust M, Meyer T, Voedisch B et al (2011) A human scFv antibody generation pipeline for proteome research. J Biotechnol 152: 159-170
33. Koide A, Bailey CW, Huang X et al (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284: 1141-1151
34. Angenendt P, Wilde J, Kijanka G et al (2004) Seeing better through a MIST: Evaluation of monoclonal recombinant antibody fragments on microarrays. Anal Chem 76:2916-2921
35. Philibert P, Stoessel A, Wang W (2007) A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 7:1472-6750
36. Parsons HL, Earnshaw JC, Wilton J et al (1996) Directing phage selections towards specific epitopes. Protein Eng 9:1043-1049
37. Lassen KS, Bradbury AR, Rehfeld JF et al (2008) Microscale characterization of the binding specificity and affinity of a monoclonal antisulfotyrosyl IgG antibody. Electrophoresis 29:2557-2564
38. Kehoe JW, Velappan N, Walbol M et al (2006) Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics 5:2350-2363
39. Hoffhines AJ, Damoc E, Bridges KG et al (2006) Detection and purification of tyrosinesulfated proteins using a novel anti-sulfotyrosine monoclonal antibody. J Biol Chem 281:37877-37887
40. Raza A, Garcia-Rodriguez C, Lou J et al (2005) Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351:158-169
41. Lee CV, Liang WC, Dennis MS et al (2004) High-affinity human antibodies from phagedisplayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340: 1073-1093
42. Hanes J, Schaffitzel C, Knappik A et al (2000) Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 18: 1287-1292
43. Schier R, McCall A, Adams GP et al (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551-567
44. Yang WP, Green K, Pinz-Sweeney S et al (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392-403
45. Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97: 10701-10705
46. Foote J, Eisen HN (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci USA 92: 1254-1256
47. Foote J, Eisen HN (2000) Breaking the affinity ceiling for antibodies and T cell receptors. Proc Natl Acad Sci USA 97:10679-10681
48. Batista FD, Neuberger MS (1998) Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity 8:751-759
49. Sidhu SS (2005) Phage display in biotechnology and drug discovery. CRC Press, Baco Raton, FL
50. Ponsel D, Neugebauer J, Ladetzki-Baehs K et al (2011) High affinity, developability and functional size: The holy grail of combinatorial antibody library generation. Molecules 16:3675-3700
51. Azzazy HM, Highsmith WE Jr (2002) Phage display technology: Clinical applications and recent innovations. Clin Biochem 35: 425-445
52. Benhar I (2007) Design of synthetic antibody libraries. Expert Opin Biol Ther 7:763-779
53. Burton DR, Barbas CF III, Persson MA et al (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 88:10134-10137
54. Kramer RA, Marissen WE, Goudsmit J et al (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35:2131-2145
55. De Carvalho NC, Williamson RA, Parren PW et al (2002) Neutralizing human Fab fragments against measles virus recovered by phage display. J Virol 76:251-258
56. Zebedee SL, Barbas CF III, Hom YL et al (1992) Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci USA 89:3175-3179
57. Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 92:6537-6541
58. Vaughan TJ, Williams AJ, Pritchard K et al (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309-314
59. Lloyd C, Lowe D, Edwards B et al (2009) Modelling the human immune response: Performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 22: 159-168
60. Sheets MD, Amersdorfer P, Finnern R et al (1998) Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95:6157-6162
61. De Haard HJ (2002) Construction of large naive Fab libraries. Methods Mol Biol 178: 87-100
62. Nissim A, Hoogenboom HR, Tomlinson IM et al (1994) Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 13:692-698
63. De Kruif J, Boel E, Logtenberg T (1995) Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol 248: 97-105
64. Griffiths AD, Williams SC, Hartley O et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245-3260
65. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227:381-388
66. Pini A, Viti F, Santucci A et al (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a twodimensional gel. J Biol Chem 273: 21769-21776
67. Hoet RM, Cohen EH, Kent RB et al (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity- determining-region diversity. Nat Biotechnol 23:344-348
68. Lee CV, Liang WC, Dennis MS et al (2004) High-affinity human antibodies from phagedisplayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340: 1073-1093
69. Söderlind E, Strandberg L, Jirholt P et al (2000) Recombining germline-derived CDR sequences for creating diverse singleframework antibody libraries. Nat Biotechnol 18:852-856
70. Rothe C, Urlinger S, Lohning C et al (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for Efficient selection of high-affinity antibodies. J Mol Biol 376:1182-1200
71. Sidhu SS, Li B, Chen Y, Fellouse FA et al (2004) Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 338:299-310
72. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 101:12467-12472
73. Fellouse FA, Li B, Compaan DM, Peden AA et al (2005) Molecular recognition by a binary code. J Mol Biol 348:1153-1162
74. Russel M, Linderoth NA, Sali A (1997) Filamentous phage assembly: Variation on a protein export theme. Gene 192:23-32
75. Iannolo G, Minenkova O, Petruzzelli R et al (1995) Modifying Filamentous phage capsid: Limits in the size of the major capsid protein. J Mol Biol 248:835-844
76. Kretzschmarm T, Geiser M (1995) Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13. Gene 155:61-65
77. Rondot S, Koch J, Breitling F et al (2001) A helper phage to improve single chain antibody presentation in phage display. Nat Biotechnol 19:75-78
78. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774
79. Edwards BM, Barash SC, Main SH et al (2003) The remarkable fl exibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol 334:103-118
80. Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253-3265
81. Lloyd C, Lowe D, Edwards B et al (2009) Modelling the human immune response: Performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 22:159-168
82. Dong J, Demarest SJ, Sereno A et al (2010) Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 9: 2593-2604
83. Doern A, Cao X, Sereno A et al (2009) Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: Implications for mechanism of action in vivo. J Biol Chem 284:10254-10267
84. Dong J, Sereno A, Snyder WB et al (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286: 4703-4717
85. Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144
86. Wu Y, Cain-Hom C, Choy L et al (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464:1052-1057
87. Xie MH, Yuan J, Adams C et al (1997) Direct demonstration of MuSK involvement in acetylcholine receptor clustering through Identification of agonist ScFv. Nat Biotechnol 15:768-771
88. Ellmark P, Andersson H, Abayneh S et al (2008) Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection. AIDS Res Hum Retroviruses 24:367-373
89. Dobson CL, Main S, Newton P et al (2009) Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs 1:552-562
90. Eisenhardt SU, Schwarz M, Bassler N et al (2007) Subtractive single-chain antibody (scFv) phage-display: Tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2:3063-3073
91. Huie MA, Cheung MC, Muench MO et al (2001) Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci USA 98:2682-2687
92. Noronha EJ, Wang X, Desai SA et al (1998) Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. J Immunol 161:2968-2976
93. Ridgway JB, Ng E, Kern JA et al (1999) Identification of a human anti-CD55 singlechain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Cancer Res 59:2718-2723
94. Van Ewijk W, De Kruif J, Germeraad WT et al (1997) Subtractive isolation of phage-displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments. Proc Natl Acad Sci USA 94:3903-3908
95. Giordano RJ, Cardo-Vila M, Lahdenranta J et al (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7: 1249-1253
96. Williams BR, Sharon J (2002) Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigenbound and free phage. Immunol Lett 81:141-148
97. Osbourn JK, Derbyshire EJ, Vaughan TJ et al (1998) Path fi nder selection: In situ isolation of novel antibodies. Immunotechnology 3:293-302
98. Osbourn JK, Earnshaw JC, Johnson KS et al (1998) Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol 16:778-781
99. Poul MA, Becerril B, Nielsen UB et al (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 301:1149-1161
100. Zhou Y, Marks JD (2009) Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol 525:145-160
101. Crépin R, Goenaga AL, Jullienne B et al (2010) Development of human single-chain antibodies to the transferrin receptor t, hat effectively antagonize the growth of leukemias and lymphomas. Cancer Res 70: 5497-5506
102. Park JW, Kirpotin DB, Hong K et al (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113
103. Nielsen UB, Kirpotin DB, Pickering EM et al (2002) Therapeutic ef fi cacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 1591:109-118
104. Velappan N, Martinez JS, Valero R et al (2007) Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein. J Immunol Methods 321:60-69
105. Cabezas S, Rojas G, Pavon A et al (2009) Phage-displayed antibody fragments recognizing dengue 3 and dengue 4 viruses as tools for viral serotyping in sera from infected individuals. Arch Virol 154:1035-1045
106. Cabezas S, Rojas G, Pavon A et al (2008) Selection of phage-displayed human antibody fragments on Dengue virus particles captured by a monoclonal antibody: Application to the four serotypes. J Virol Methods 147: 235-243
107. Lim AP, Chan CE, Wong SK et al (2008) Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J 5:130
108. Okada J, Ohshima N, Kubota-Koketsu R et al (2010) Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classi fi ed into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. Virology 397:322-330
109. Meissner F, Maruyama T, Frentsch M et al (2002) Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay. Virology 300:236-243
110. Kirsch MI, Hülseweh B, Nacke C et al (2008) Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 8:66
111. Hayhurst A, Happe S, Mabry R et al (2003) Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods 276:185-196
112. Zou N, Newsome T, Li B et al (2007) Human single-chain Fv antibodies against Burkholderia mallei and Burkholderia pseudomallei . Exp Biol Med (Maywood) 232:550-556
113. Maynard JA, Maassen CB, Leppla SH et al (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20:597-601
114. Wild MA, Xin H, Maruyama T et al (2003) Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 21:1305-1306
115. Steiniger SC, Altobell LJ 3rd, Zhou B, Janda KD (2007) Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen. Mol Immunol 44:2749-2755
116. Pelat T, Hust M, Laf fl y E et al (2007) High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51:2758-2764
117. Cirino NM, Sblattero D, Allen D et al (1999) Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun 67:2957-2963
118. Zhou B, Wirsching P, Janda KD (2002) Human antibodies against spores of the genus Bacillus: A model study for detection of and protection against anthrax and the bioterrorist threat. Proc Natl Acad Sci USA 99:5241-5246
119. Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273
120. Sun L, Lu X, Li C et al (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476
121. Throsby M, Van Den Brink E, Jongeneelen M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM + memory B cells. PLoS One 3:e3942
122. Ayriss J, Woods T, Bradbury A, Pavlik P (2007) High-throughput screening of singlechain antibodies using multiplexed flow cytometry. J Proteome Res 6:1072-1082
123. Pershad K, Pavlovic JD, Gräslund S et al (2010) Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display. Protein Eng Des Sel 23:279-288
124. Parsons HL, Earnshaw JC, Wilton J et al (1996) Directing phage selections towards specific epitopes. Protein Eng 9:1043-1049
125. Mutuberria R, Satijn S, Huijbers A et al (2004) Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods 287:31-47
126. Cohen CJ, Denkberg G, Lev A et al (2003) Recombinant antibodies with MHCrestricted, peptide-specific, T-cell receptorlike specificity: New tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit 16:324-332
127. Engberg J, Krogsgaard M, Fugger L (1999) Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: Novel reagents for basic and clinical investigations and immunotherapy. Immunotechnology 4:273-278
128. Stryhn A, Andersen PS, Pedersen LO et al (1996) Shared fi ne specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc Natl Acad Sci USA 93:10338-10342
129. Villa A, Trachsel E, Kaspar M et al (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin ef fi ciently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405-2413
130. Pini A, Viti F, Santucci A et al (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a twodimensional gel. J Biol Chem 273: 21769-21776
131. Schliemann C, Neri D (2010) Antibodybased vascular tumor targeting. Recent Results Cancer Res 180:201-216
132. Nizak C, Monier S, del Nery E et al (2003) Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 300:984-987
133. Gao J, Sidhu SS, Wells JA (2009) Two-state selection of conformation-specific antibodies. Proc Natl Acad Sci USA 106:3071-3076
134. Eisenhardt SU, Schwarz M, Bassler N, Peter K (2007) Subtractive single-chain antibody (scFv) phage-display: Tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2:3063-3073
135. Rothlisberger D, Pos KM, Pluckthun A (2004) An antibody library for stabilizing and crystallizing membrane proteins-selecting binders to the citrate carrier CitS. FEBS Lett 564:340-348
136. Uysal S, Vásquez V, Tereshko V et al (2009) Crystal structure of full-length KcsA in its closed conformation. Proc Natl Acad Sci USA 106:6644-6649
137. Ye JD, Tereshko V, Frederiksen JK et al (2008) Synthetic antibodies for specific recognition and crystallization of structured RNA. Proc Natl Acad Sci USA 105:82-87
138. Koldobskaya Y, Duguid EM, Shechner DM et al (2010) A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination. Nat Struct Mol Biol 18:100-106
139. Monigatti F, Gasteiger E, Bairoch A, Jung E (2002) The Sul fi nator: Predicting tyrosine sulfation sites in protein sequences. Bioinformatics 18:769-770
140. Kehoe JW, Velappan N, Walbolt M et al (2006) Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics 5:2350-2363
141. Thie H, Voedisch B, Dübel S et al (2009) Affinity maturation by phage display. Methods Mol Biol 525:309-322
142. Cadwell RC, Joyce GF (1994) Mutagenic PCR. PCR Methods Appl 3:S136-S140
143. Stemmer WP (1994) DNA shuf fl ing by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91:10747-10751
144. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 101:12467-12472
145. Liang WC, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951-961
146. Lee CV, Hymowitz SG, Wallweber HJ et al (2006) Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 108:3103-3111
147. Fagète S, Ravn U, Gueneau F et al (2009) Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent. MAbs 1:288-296
148. Bostrom J, Yu SF, Kan D et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610-1614
149. Volk WA, Bizzini B, Snyder RM et al (1984) Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 45:604-609
150. Zwick MB, Labrijn AF, Wang M et al (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905
151. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Eng J Med 359:613-626
152. De Kruif J, Logtenberg T (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem 271: 7630-7634
153. Thie H, Binius S, Schirrmann T et al (2009) Multimerization domains for antibody phage display and antibody production. New Biotechnol 26:314-321
154. Hudson PJ, Kortt AA (1999) High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231:177-189
155. Dübel S, Breitling F, Kontermann R et al (1995) Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J Immunol Methods 178:201-209
156. Huang D, Shusta EV (2006) A yeast platform for the production of single-chain antibodygreen fluorescent protein fusions. Appl Environ Microbiol 72:7748-7759
157. Hink MA, Griep RA, Borst JW et al (2000) Structural dynamics of green fluorescent protein alone and fused with a single chain Fv protein. J Biol Chem 275:17556-17560
158. Casey JL, Coley AM, Tilley LM et al (2000) Green fluorescent antibodies: Novel in vitro tools. Protein Eng 13:445-452
159. Griep RA, Van Twisk C, Kerschbaumer RJ et al (1999) pSKAP/S: An expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. Protein Expr Purif 16:63-69
160. Al-Mrabeh A, Ziegler A, Cowan G et al (2009) A fully recombinant ELISA using in vivo biotinyla.ted antibody fragments for the detection of potato leafroll virus. J Virol Methods 159:200-205
161. Predonzani A, Arnoldi F, Lopez-Requena A et al (2008) In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol 8:41
162. Warren DJ, Bjerner J, Paus E et al (2005) Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 51: 830-838
163. Cloutier SM, Couty S, Terskikh A et al (2000) Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol Immunol 37:1067-1077
164. Moutel S et al (2009) A multi-Fc-species system for recombinant antibody production. BMC Biotechnol 9:14
165. Hu S, Shively L, Raubitschek A et al (1996) Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (singlechain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055-3061
166. Gilliland LK, Norris NA, Marquardt H et al (1996) Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47:1-20
167. Shan D, Press OW, Tsu TT et al (1999) Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 162:6589-6595
168. Kontermann RE (2010) Alternative antibody formats. Curr Opin Mol Ther 12:176-183
169. Merchant AM, Zhu Z, Yuan JQ et al (1998) An Efficient route to human bispecific IgG. Nat Biotechnol 16:677-681
170. Ridgway JB, Presta LG et al (1996) 'Knobsinto-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617-621
171. Coloma MJ, Morrison SL (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159-163
172. Dong J, Sereno A, Snyder WB et al (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286:4703-4717
173. Kortt AA, Dolezal O, Power BE et al (2001) Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 18: 95-108
174. Lawrence LJ, Kortt AA, Iliades P et al (1998) Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett 425:479-484
175. Perisic O, Webb PA, Holliger P et al (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217-1226
176. Atwell JL, Breheney KA, Lawrence LJ et al (1999) scFv multimers of the antineuraminidase antibody NC10: Length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 12: 597-604
177. Pei XY, Holliger P, Murzin AG et al (1997) The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94:9637-9642
178. Le Gall F, Kipriyanov SM, Moldenhauer G et al (1999) Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding. FEBS Lett 453:164-168
179. Muller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24:89-98
180. Beck A, Wagner-Rousset E, Bussat MC et al (2008) Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9:482-501
181. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460-470
182. Hallborn J, Carlsson R (2002) Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques Suppl, 30-37
183. Lou J, Marzari R, Verzillo V et al (2001) Antibodies in haystacks: How selection strategy in fl uences the outcome of selection from molecular diversity libraries. J Immunol Methods 253:233-242
184. Kawe M, Forrer P, Amstutz P et al (2006) Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem 281: 40252-40263
185. Glanville J, Zhai W, Berka J et al (2009) Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 106:20216-20221
186. Ravn U, Gueneau F, Baerlocher L et al (2010) By-passing in vitro screening-next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Res 38:e193
187. Ge X, Mazor Y, Hunicke-Smith SP et al (2010) Rapid construction and characterization of synthetic antibody libraries without DNA amplification. Biotechnol Bioeng 106: 347-357
188. Fischer N (2011) Sequencing antibody repertoires: The next generation. MAbs 3: 17-20
189. Reddy ST, Ge X, Miklos AE et al (2010) Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol 28: 965-969
190. Zhang H, Torkamani A, Jones TM et al (2011) Phenotype-information- phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems. Proc Natl Acad Sci USA 108: 13456-13461
191. Bordeaux J, Welsh A, Agarwal S et al (2010) Antibody validation. Biotechniques 48: 197-209
192. Pozner-Moulis S, Cregger M, Camp RL et al (2007) Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87:251-260
193. Grimsey NL, Goodfellow CE, Scotter EL et al (2008) Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods 171:78-86
194. Saper CB (2005) An open letter to our readers on the use of antibodies. J Comp Neurol 493:477-478